Crinetics Pharmaceuticals to Participate in Investor Conferences
Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company committed to discovering and commercializing innovative therapies for endocrine diseases and related tumors, has announced its participation in two important investor conferences. Management will take part in fireside chats at both the Morgan Stanley 22nd Annual Global Healthcare Conference and the Cantor Global Healthcare Conference, scheduled for September.
Morgan Stanley 22nd Annual Global Healthcare Conference
At the Morgan Stanley 22nd Annual Global Healthcare Conference, Crinetics Pharmaceuticals will host a fireside chat on Wednesday, September 4, at 5:35 p.m. Eastern Time. This session will offer insights into the company’s innovative strategies and recent advancements.
Webcast Information
You can access the live webcast HERE.
Cantor Global Healthcare Conference
Crinetics will also be featured at the Cantor Global Healthcare Conference. The fireside chat is set for Wednesday, September 18, at 8:35 a.m. Eastern Time, where the company will outline its strategic vision and upcoming milestones.
Webcast Information
The live webcast link for this session can be found HERE.
Accessing Webcasts
Both live and archived webcasts from these conferences will be accessible on the Events & Presentations page within the Investors section of Crinetics’ official website at www.crinetics.com/events.
Opportunities for Meetings
Investors who wish to schedule one-on-one meetings with management during the conferences are encouraged to contact their respective conference representatives. This will provide an opportunity for more detailed discussions about Crinetics’ current projects and future plans.
About Crinetics Pharmaceuticals
Crinetics Pharmaceuticals is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of novel therapeutics for endocrine diseases and tumors. One of their key candidates is paltusotine, a first-in-class oral somatostatin receptor type 2 (SST2) agonist, currently in Phase 3 clinical trials for acromegaly and Phase 2 trials for carcinoid syndrome associated with neuroendocrine tumors.
Recent Developments
Additionally, Crinetics is progressing with atumelnant (CRN04894), another first-in-class oral ACTH antagonist, which is nearing the completion of Phase 2 clinical studies for conditions like congenital adrenal hyperplasia and Cushing’s disease. The company emphasizes that all drug candidates are small-molecule entities developed through extensive in-house research.
Addressing a Range of Conditions
Crinetics is also focused on tackling various endocrine conditions, such as hyperparathyroidism, polycystic kidney disease, Graves’ disease, diabetes, obesity, and cancer indications that target GPCRs. Their dedication to innovative therapies underscores their significance in the medical community.
Investor Contacts
If you have any questions regarding investments or would like to reach out to management, please contact:
Gayathri Diwakar
Head of Investor Relations
gdiwakar@crinetics.com
(858) 345-6340
Media Contacts
For media inquiries, please reach out to:
Natalie Badillo
Head of Corporate Communications
nbadillo@crinetics.com
(858) 345-6075
Frequently Asked Questions
What is the focus of Crinetics Pharmaceuticals?
Crinetics Pharmaceuticals specializes in developing therapeutics for endocrine diseases and related tumors.
What investor conferences is Crinetics participating in?
Crinetics will be taking part in the Morgan Stanley and Cantor Global Healthcare Conferences.
Who can schedule meetings with Crinetics management?
Investors can arrange meetings through their conference representatives.
What is paltusotine?
Paltusotine is an oral somatostatin receptor type 2 agonist currently in Phase 3 clinical development for acromegaly.
How can I access the webcasts from the conferences?
The webcasts will be available on the Events & Presentations page of the Crinetics website.